Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses

Jiun Ruey Hu, Meredith S. Duncan, Alicia K. Morgans, Jonathan D. Brown, Wouter C. Meijers, Matthew S. Freiberg, Joe Elie Salem, Joshua A. Beckman, Javid J. Moslehi

Research output: Contribution to journalReview articlepeer-review

100 Scopus citations


Androgen deprivation therapy is a cornerstone of prostate cancer treatment. Pharmacological androgen deprivation includes gonadotropin-releasing hormone agonism and antagonism, androgen receptor inhibition, and CYP17 (cytochrome P450 17A1) inhibition. Studies in the past decade have raised concerns about the potential for androgen deprivation therapy to increase the risk of adverse cardiovascular events such as myocardial infarction, stroke, and cardiovascular mortality, possibly by exacerbating cardiovascular risk factors. In this review, we summarize existing data on the cardiovascular effects of androgen deprivation therapy. Among the therapies, abiraterone stands out for increasing risk of cardiac events in meta-analyses of both randomized controlled trials and observational studies. We find a divergence between observational studies, which show consistent positive associations between androgen deprivation therapy use and cardiovascular disease, and randomized controlled trials, which do not show these associations reproducibly.

Original languageEnglish
Pages (from-to)E55-E64
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Issue number3
StatePublished - Mar 1 2020

Bibliographical note

Publisher Copyright:
© 2020 American Heart Association, Inc.


  • androgen deprivation therapy
  • cardiooncology
  • cardiotoxicity
  • gonadotropin releasing hormone agonists
  • prostate cancer

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses'. Together they form a unique fingerprint.

Cite this